ArticleAdvances in experimental medicine and biology2025
IGFBP5 as a Novel Basolateral Secretion Marker in the Retinal Pigment Epithelium.
Article in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The retinal pigment epithelium (RPE) is a highly polarized cell type in the retina which is specialized to support the photoreceptors and choroid. To assess the adequacy of RPE polarity in culture or altered RPE polarity under disease conditions in vivo, the polarized secretion of particular proteins can be monitored. Currently accepted basolateral secretion markers for RPE include the pro-angiogenic factor, VEGF, and extracellular matrix remodeling protein, TIMP-3. However, VEGF secretion is low enough that it often requires ELISA for detection, and TIMP-3 secretion is only modestly polarized to the basolateral side. We sought out an improved marker of basolateral secretion that is both highly expressed and highly polarized. Through a combination of bioinformatics analysis and RPE cell culture experiments, we identify insulin growth factor binding protein 5 (IGFBP5) as a more robust and convenient RPE basolateral marker compared to TIMP-3 and VEGF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.